Development of gut microbiota modulators to regulate metabolic disorders

Microbiota, | Probiotics | Diabetes | Glycemia


Genbioma is a biotech startup from Navarra dedicated to the development and commercialization of products based on the study of the microbiome to regulate metabolic disorders and improve health. 

The aim is to offer natural nutritional solutions capable of differentially improving factors in the short and long term and preventing the development of increasingly prevalent pathologies – such as diabetes, cardiovascular risk, and obesity – by studying the impact on the intestinal microbiota.

The company’s main objective is focused on the development and commercialization of products with probiotic activity (live microorganisms) and postbiotics (metabolites obtained from microorganisms inactivated by heat) that are safe and effective for the regulation of blood glucose for different profiles of people with Diabetes (Prediabetes, Type 2 Diabetes, Gestational Diabetes).

The efficacy of these products is based on the activity of a proprietary collection of bacteria with the ability to regulate blood glucose which, as a result of the research carried out, have been patented by Genbioma. The first products have been developed in the form of a probiotic ingredient based on the microbial strain Pediococcus acidilactici (pA1c®) and its postbiotic version (pA1c®HI), as well as versions in the form of nutritional supplements (Reglubetic® and Reglubetic®HI).

Genbioma brings a clearly differential value to the market offer since it offers, on the one hand, a nutritional strategy based on the study of the Microbiome and, on the other hand, its impact on the Microbiota to prevent Diabetes based on certain probiotic bacteria that help to specifically activate our metabolism.

The products developed by Genbioma are natural ingredients (probiotics and postbiotics) that are consumed within a healthy diet and help to delay or reverse the risk and complications of Diabetes according to the profile and degree of evolution of the disease (Type 2 Diabetes, Prediabetes, and Gestational Diabetes).

As a novelty, the postbiotic version pA1c®HI has also been shown to have an effective product for blood glucose regulation and a shelf life far superior to probiotics (up to 3 years in any climatic condition). Currently, there are no references of products of any kind in the Consumer Health market aimed at this population niche with Prediabetes, which is highly prevalent both nationally and internationally, with a growing incidence data and higher than the prevalence of diabetes.

In addition, to date, there is no postbiotic capable of regulating blood glucose in people with glycemic metabolic disorders, especially in the population with Prediabetes and Gestational Diabetes. The company’s vision clearly focuses on international commercialization from the basis of generating science for the industrial development of safe, scientifically validated probiotics at an affordable cost, democratizing the market price to reach the maximum number of people with diabetes.

We are aware that the prevalence of Diabetes in all its varieties continues to increase, and the strategies developed to date have not been able to stop the advance of this pandemic.

Featured proyects

– EIT Food Accelerator Network (FAN): selected among 600 international startups within EIT Food Europe July 2021

– Recognized as the most innovative start-up in Navarra in the EmprendeXXI 2023 Awards, by CaixaBank Day One.

– Probiota Pioneers Award 2022
This European award recognizes the most innovative and promising start-ups in the field of microbiome science internationally. The prize is awarded annually at the Probiota Global event, which brings together international experts from academia, industry and regulation. (